Concepedia

Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines

Lei Zhao, Tingting Fan, Zhichao Shi, Chao Ding, Cunlong Zhang, Zigao Yuan, Qinsheng Sun, Chunyan Tan, Bizhu Chu, Yuyang Jiang

European Journal of Medicinal Chemistry · 2021 · 23 citations · 35 references

DOIFull text

Open access

Concepts

References

35

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 87.7K citations · Full text

, , +16

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

, , +17

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

William Pao, Vincent A. Miller, Katerina Politi et al. · PLoS Medicine · 2005 · 3.5K citations · Full text

, , +17

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms et al. · Proceedings of the National Academy of Sciences · 2008 · 2.1K citations · Full text

, , +14

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

, , +11